Drug Trial Radar · NCT07646626
SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jul 17, 2026
Primary completion
Jun 30, 2027
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.
Conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
Interventions
SSGJ-705Drug
anti-PD-1 and anti-HER2 bispecifc antibody
SSGJ-612Drug
anti-HER2 antibody
SSGJ-705 combined with chemotherapyDrug
SSGJ-705 combined with chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: 12 months
- Incidence of Treatment-Emergent Adverse EventsTime frame: 12 months
- Severity of Treatment-Emergent Adverse EventsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.